



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 38823

Title: Systematic Literature Review of the Antitumor Effect of Octreotide in Neuroendocrine Tumors

Reviewer's code: 02542653

Reviewer's country: Japan

Science editor: Xue-Jiao Wang

Date sent for review: 2018-03-23

Date reviewed: 2018-03-25

Review time: 2 Days

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input checked="" type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

Our interests for SSA (Octreotide and/or Lanreotide) are 1) if disease progression, treatment with SSA should be continued in combination with any of the subsequent options or not. Please mention about this clinical question. Another question is does Octreotide effect except mid-gut. However, these table and main text does not mention about primary site. Please clarify the primary site in table and mention about this point in discussion.



PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 38823

Title: Systematic Literature Review of the Antitumor Effect of Octreotide in Neuroendocrine Tumors

Reviewer's code: 03252959

Reviewer's country: Italy

Science editor: Xue-Jiao Wang

Date sent for review: 2018-03-23

Date reviewed: 2018-03-31

Review time: 8 Days

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

COMMENTS TO AUTHORS

The manuscript is well ideated and conducted; it is concise with adequate complementary material; it is also well written. However there are sufficient clinical trials and recent literature reviews to support the use of Octreotide as an effective antitumor agent for neuroendocrine tumours. I think that this manuscript has a really limited impact on the current literature, so I suggest the authors to submit it to a journal with a lower impact.